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Abstract
Viral genotype assessment is important for effective clinical management of HIV-1 infected patients, especially when access and/or
adherence to antiretroviral treatment is reduced. In this study, we describe development of a matrix-assisted laser desorption/ionization-
time of flight mass spectrometry-based viral genotyping assay, termed restriction fragment mass polymorphism (RFMP). This assay is
suitable for sensitive, specific and high-throughput detection of multiple drug-resistant HIV-1 variants. One hundred serum samples from 60
HIV-1-infected patients previously exposed to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs) and protease inhibitors (PIs) were analysed for the presence of drug-resistant viruses using the RFMP and direct
sequencing assays. Probit analysis predicted a detection limit of 223.02 copies/mL for the RFMP assay and 1268.11 copies/mL for the direct
sequencing assays using HIV-1 RNA Positive Quality Control Series. The concordance rates between the RFMP and direct sequencing
assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97%
(Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100%
(I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in the protease coding region. Defined mixtures were consistently and
accurately identified by RFMP at 5% relative concentration of mutant to wild-type virus while at 20% or greater by direct sequencing. The
RFMP assay based on mass spectrometry proved to be sensitive, accurate and reliable for monitoring the emergence and early detection of
HIV-1 genotypic variants that lead to drug resistance.
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Introduction
Highly active antiretroviral therapy (HAART) can dramati-
cally suppress HIV-1 replication, improve immunological
response and extend a patient’s lifespan. However, less than
excellent adherence to HAART or conditions that result in
reduced treatment efficacy leads to a higher risk of the
emergence of antiretroviral (ARV) drug-resistant viral strains,
which eventually leads to increased viral loads, poor
immunological response and eventually treatment failure
[1]. Especially, women who have received single-dose
nevirapine to prevent mother-to-child HIV-1 transmission
are at increased risk of virological failure as a result of the
replication of low-abundance nevirapine-resistant variants
when treated with a subsequent nevirapine-containing reg-
imen [2]. Of importance in the effective management of HIV-1
infections is the timely and efficient detection of
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drug-resistant viral strains and their specific mutations in a
patient’s clinical samples.
The guidelines for use of ARV drugs in HIV-1-infected adults
and adolescents established by the US Department of Health
and Human Services (DHHS) (http://www.aidsinfo.nih.gov/
guidelines) recommend monitoring viral genotypic changes in
patient samples and use of this information to determine which
therapeutic regimens are most appropriate for the specific
patient [3].
The restriction fragment mass polymorphism (RFMP)
method is based on amplification and mass detection of
oligonucleotides excised by type-IIS restriction enzyme diges-
tion, using matrix-assisted laser desorption and ionization time
of flight mass spectrometry (MALDI-TOF MS). RFMP-based
drug-resistance testing and genotyping has been shown to be a
sensitive, accurate and reliable method for clinical utility in
many fields [4–12]. Especially important is that RFMP enables
sensitive detection of mutations without population-based
cloning and subsequent sequencing analysis [6].
In this study, we applied the RFMP assay for detection of
mutations in the coding sequences for reverse transcriptase
(RT) and protease (PR) of HIV-1 that engender resistance to
nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and
protease inhibitors (PIs). Compared with direct sequencing,
RFMP is shown to be a sensitive and reliable method for
genotypic testing of drug-resistance mutations in HIV-1
infected patients.
Materials and Methods
Specimens
A total of 100 plasma samples were collected from 60 HIV-1
infected patients who had received HAART (including NRTIs,
NNRTIs and PIs) at the AIDS Clinical Center, National Center
for Global Health and Medicine, Japan, between 1999 and
2009. Written informed consent was obtained from each
participant, and the experimental protocol conformed to the
ethical guidelines of the 1975 Declaration of Helsinki, as
reflected in a priori approval (NCGM-H22-938) by the Ethics
Committee of the AIDS Clinical Center, National Center for
Global Health and Medicine, Japan. The demographic charac-
teristics are summarized in Table 1.
HIV-1 performance panels
To assess the limit of detection ability of the RFMP assay, the
HIV-1 RNA Positive Quality Control Series (ACCURUN
315) obtained from SeraCare Life Sciences (Milford, MA, USA)
was used to measure viral load in HIV-1 performance panels.
Construction of recombinant HIV-1 clones
Recombinant infectious HIV-1 clones with various mutations in
the RT region were constructed using site-directed mutagen-
esis. Briefly, the mutations were introduced into the XmaI-
NheI fragment (759 bp) of pTZNX1, which encodes Gly-15 to
Ala-267 of HIV-1 RT (strain BH 10), by oligonucleotide-based
mutagenesis [13]. The XmaI-NheI fragment was inserted into a
pNL4-3-based plasmid, generating various molecular clones
with the desired mutations. Each molecular clone (10 /mL as
DNA) was transfected into human 293T cells (4 9 105 cells/
100-mm-diameter dish) with Fugene transfection reagent
(Roche Diagnosis, Basel, Switzerland). After 48 h, culture
supernatants were harvested and stored at 80°C until use.
Viral loads were determined using the COBAS Amplicor
HIV-1 Monitor Test, v1.5.
RNA extraction and cDNA amplification
HIV-1 RNA was extracted from 200 lL of plasma using the
High Pure Viral RNA Kit (Roche Diagnostics, Mannheim,
Germany) according to manufacturer’s instructions. Purified
viral RNA was dissolved in 50 lL elution buffer (nuclease-free,
sterile, double distilled water). cDNA was synthesized using
only the reverse transcription step component of the RNA
PCR kit (TaKaRa, Otsu, Japan).
TABLE 1. Demographic characteristics of 60 HIV-1-infected
patients
Characteristic Value
Mean age in years (range) 42 (22–67)
No. male (%) 53 (88)
No. female (%) 7 (12)
Race (%)
Asian 58 (97)
African 2 (3)
Risk factor for HIV (% of patients)
Heterosexual 14 (23)
Homosexual 27 (45)
Haemophilia (infected blood products) 19 (32)
CDC clinical stage (%)
A1/A2/A3 0/0/0
B1/B2/B3 17/23/13
C1/C2/C3 5/12/20
Unknown 10
Mean CD4 cell count (No. of cells/uL [range]) 320 (12–759)
No. of unknown (%) 3 (5)
Mean HIV-1 RNA (No. of RNA copies/mL [range]) 43 000 (50–1 200 000)
No. of unknown (%) 6 (10)
History of actual treatment (No. of patients)
With NRTI 2
With NRTI plus NNRTI 23
With NRTI plus PI 21
With NNRTI plus PI 1
With NRTI plus NNRTI plus PI 33
With NRTI plus PI plus INI 1
With NRTI plus INI 2
With NRTI plus PI plus INI plus FI 1
With NRTI plus NNRTI plus PI plus INI plus FI 1
Interruption 15
NRTI, nucleoside reverse transcriptase inhibitor; lamivudine, abacavir, emtricita-
bine, tenofovir, stavudine, didanosine, zidovudine; NNRTI, non-nucleoside reverse
transcriptase inhibitor; efavirenz, nevirapine; PI, protease inhibitor; atazanavir,
ritonavir, lopinavir, darunavir, fosamprenavir, amprenavir, nelfinavir; INI, integrase
inhibitor; raltegravir; FI, fusion inhibitor; enfuvirtide.
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RFMP assay
PCR reactions were performed in 25 lL reaction mixtures
containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 0.2 mM
deoxynucleoside triphosphates (dNTPs), 10 pmol of primers
and 0.4 U of Platinum Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA). The initial denaturing phase of 5 min at
94°C was followed by a 35-cycle amplification phase containing
a denaturation step at 94°C for 15 s, annealing step at 50°C
for 15 s and elongation step at 72°C for 15 s, and completed
with a final extension phase at 72°C for 5 min. For the RFMP
analysis of codons 65, 69, 74, 103, 106, 151, 181, 184 and 215
in the HIV-1 RT region and codons 30, 46, 48, 50, 54, 82, 84
and 90 in the HIV-1 PR region, each of the forward and reverse
primers contained the viral target sequence and the FokI
recognition sequence ggatg (Table S1). Restriction enzyme
digests were performed by mixing the PCR reaction with
10 lL of buffer (50 mM potassium acetate, 20 mM Tris-
acetate, 10 mM magnesium acetate and 1 mM dithiothreitol)
and 1 U of FokI enzyme (New England Biolabs, Beverly, MA,
USA). The reaction mixtures were incubated at 37°C for 2 h.
Subsequently, the digest desalting and mass analysis were
performed as described previously [14].
MALDI-TOF instrumentation and calibration
Mass spectra were acquired on a Biflex IV linear MALDI-TOF
MS (Bruker Daltonics) workstation equipped with a 337 nm
nitrogen laser and a nominal ion flight path length of 1.25 m.
The samples were analyzed in the negative-ion mode with a
total acceleration voltage of 20 kV, extraction voltage of
18.25 kV, laser attenuation of 55, and delayed extraction of
long time delay mode. Typically, time-of-flight data from 20 to
50 individual laser pulses were recorded and averaged on a
transient digitizer with a time base of 2 ns and delay of
24 000 ns, after which the averaged spectra were automati-
cally converted to mass by the accompanying data-processing
software. Using these settings the instrument typically pro-
vided mass accuracy of 40–80 ppm (106), mass resolution of
1500–2000 and sensitivity of 10–50 fmol in the 2- to 6-kDa
mass range for oligonucleotides. Oligonucleotide standards of
6mer (5′-ACGTAC-3′; 1762.2 Da) and 16mer (5′-AC
GTACGTACGTACGT-3′; 4881.2 Da) with no terminal phos-
phate were used for mass calibration of the instrument. The
presence of metal cations produces salt adducts, leading to
reduced resolution and low sensitivity, so C18 reverse phase
micro-column chromatography was used for desalting oligo-
nucleotides. Non-homogeneous crystallization is obtained with
the classic dried droplet preparation, and a search for a ‘sweet
spot’ is required. Re-crystallization of sample DNAs on matrix-
prespotted anchorchip plates allowed robust formation of
small single crystals.
Direct sequencing assay
To amplify the HIV-1 RT and PR regions for analysis by direct
sequencing, PCR was performed with the following primers: 5′-
AACAATGGCCATTGACAGAAGAAA-3′ (2614–2637 bp of
HXB2), 5′-CTGTATGTCATTGACAGTCCAGCT-3′ (3299–
3323 bp of HXB2) for the RT region and 5′-CTTCCCTCA
GATCACTCTTTGGCAA-3′ (2248–2273 bp of HXB2), 5′-
AGGGCTAATGGGAAAATTTAAAGT-3′ (2238–2561 bp of
HXB2) for the PR region. PCR products were sequenced using
the BigDye Terminator (version 3.1) Cycle Sequencing kit and
an ABI PRISM 310 Analyzer (Applied Biosystems, Foster City,
CA, USA).
Statistics
A limit of detection test was performed by probit analysis to
compare sensitivity between the RFMP and direct sequencing
assays using the statistical package SAS (version 8; SAS
Institute Inc., Cary, NC, USA).
Results
RFMP assay strategy
The RFMP assay is based onmass spectrometric analysis of small
DNA fragments that include sites of mutation (Fig. S1). The first
step requires PCR amplification with forward and reverse
primers that introduce the FokI enzyme site, ggatg (Table S1).
Thediagnostic fragments releasedbyenzymatic digestion consist
of various sizes from 8 nt oligomers to 14 nt oligomers for nine
codons in the RT region and eight codons in the PR region,
leading to facile identification of sequence variation by mass
spectrum analysis. Genotypic analysis ofmutations at codons 65,
69, 74, 103, 106, 151, 181, 184 and 215 in the RT region and
codons 30, 46, 48, 50, 54, 54, 82, 84 and 90 in the PR region, as
assessed by the RFMP assay, was determined for 100 plasma
samples. The RFMP results showed distinct peaks relevant to
each codon, with the mass values for each diagnostic fragment
being exactly as predicted (Supplementary Material Table S2).
Estimation of limit of detection and ability to detect mixed
genotype populations
The detection limit was estimated using replicates of each of
nine dilutions of HIV-1 RNA Positive Quality Control Series
(ACCURUN 315) material ranging between 10 and 5000
copies/ml. Analysis of various calibrated HIV-1 RNA dilution
series determined the lower detection limit to be 223.02 cop-
ies/mL for the RFMP and 1268.11 copies/mL for the direct
sequencing assays by probit analysis. The probit analysis
predicts a 95% CI: 132.64–693.00 for the RFMP and 863.09–
3656.80 for the direct sequencing assays (Table 2).
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To evaluate the ability of the RFMP assay to determine small
amounts of mutant virus in mixed populations, assays were
performed with recombinant HIV-1 clones composed of
different ratios of wild-type (K103 in the RT region) and mutant
genotypes (N103 in the RT region). Defined mixtures were
prepared with the following percentages of K103Nmutant virus
in the total virus population: 100%, 50%, 20%, 10%, 5% and 1%.
The K103Nmutant virus could be detected in concentrations as
low as 5% of the total virus by RFMP, whereas direct sequencing
assays were able to detect mutant virus only when present in
20% or more of the total virus population (Fig. 1).
Comparison of RFMP with direct sequencing analyses
All 100 clinical samples from 60 patients were analysed by the
RFMP and direct sequencing assays for the presence of drug
resistance-related mutations: nine codons in the RT region and
eight codons in the PR region of the HIV-1 pol gene (a total of
17 codons).
The overall concordance rates between RFMP and sequenc-
ing assays were excellent, irrespective of PR and RT regions
(Table 3). Concordance rates in the RT region were 97% (97/
100) at codons 65, 69, 74, 103, 151, 181 and 184, 96% (96/100)
at codon 106, and 94% (94/100) at codon 215 (Fig. 2a).
TABLE 2. Limit of detection of the RFMP and direct sequencing assays
HIV-1 RNA copies/ml No. tested
RFMP Direct sequencing
No. detected Per cent detected No. detected Per cent detected
5000 10 10 100% 10 100%
2500 10 10 100% 10 100%
1000 10 10 100% 9 90%
500 10 10 100% 4 40%
250 10 10 100% 1 10%
100 10 8 80% 0 0%
50 10 3 30% 0 0%
25 10 1 10% 0 0%
10 10 1 10% 0 0%
Limit of detection 223.02 copies/mL (95% CI, 132.64–693.00) 1268.11 copies/mL (95% CI, 863.09–3656.80)
Defined dilutions of HIV-1 RNA Positive Quality Control Series were made from 10 copies to 5000 copies/mL and limit of detection abilities were calculated by probit analysis at a
95% detection level.
(a)
(b)
(c)
(d)
(e)
(f)
FIG. 1. Evaluation of the sensitivity of the RFMP assay for detection of minor amounts of virus with a defined mixture of K103N. The MALDI-TOF
MS spectra and direct sequencing chromatograms shown are representative of experiments repeated three times using mixed populations of wild-
type (K103) and NNRTI mutant (N103). The wild-type plasmids were mixed with mutant type at various ratios as follows: (a) 100%, (b) 50%, (c) 20%,
(d) 10%, (e) 5% and (f) 1%. Molecular masses of 3133.0 and 3157.0 correspond to N103 and K103, respectively. AI is absolute intensity; m/z is mass-
to-charge ratio.
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Similarly, concordance rates in the PR region were 100% (100/
100) at codons 30, 46, 48, 50, 54 and 90, and 99% (99/100) at
codons 82 and 84 in the PR region (Fig. 2b). Both assays
showed identical base substitution and amino acid composition
in these positions. Rate of compatible cases were observed 1%
(1/100) at codons 106, and 3% (3/100) at codon 215 in the RT
region and 1% (1/100) at codons 82 and 84 in the PR region,
respectively. Three samples (mixed-type) at codon 215
containing double mutations in a single codon were identified
only by RFMP, as a result of the inability of the direct
sequencing assay to determine the variants present in the
clinical samples. As shown in Fig 2(c), 215T/Y mixtures
detected by RFMP could be scored as 215T (ACC) plus
215Y (TAC), or 215N (AAC) plus 215S (TCC), or 215T
(ACC) plus 215S (TCC) plus 215Y (TAC), by direct sequenc-
ing. A compatible single nucleotide mixture at one position
was observed in three samples at three codons (codon 106 in
the RT; codon 82, 84 in the PR), respectively. Of these, the
RFMP assay detected more mixed samples than the direct
sequencing assay. The details of mixtures detected by both
assays are shown in Table 3. Discordances between the two
assays occurred for three samples at RT region codons, which
had undetectable viral loads; the correct viral genotypes were
identified only by RFMP assay.
Discussion
ARV drug-resistance is a major obstacle in the effective clinical
management of HIV-1-infected patients [3,15] and therapeutic
strategies must maximize the early detection of drug resis-
tance mutations. Having a sensitive genotyping assay that can
detect with high accuracy and reliability, drug-resistance
mutations that emerge during HAART can be very important
for the optimization of ARV regimens, improvement of patient
treatment and outcome of therapy. The RFMP assay has been
demonstrated to be a sensitive, accurate and reliable method
for genotyping and detecting drug-resistance mutations in
several viruses, including hepatitis and papillomavirus [4,6,8–
12].
In the present study, we validated use of the MALDI-TOF
MS-based RFMP assay to detect oligonucleotides containing
8–14 nucleotides for codons implicated with ARV drug-
resistance mutations. Specifically, we established successful
detection at codons 65, 69, 74, 103, 106, 151, 181, 184 and
215 in the HIV-1 RT coding region, and 30, 46, 48, 50, 54, 82,
84 and 90 in the HIV-1 PR coding region. These codons
address resistance to all approved NRTI and NNRTI
inhibitors [16–18]: mutation at RT codon 65 (K65R) confers
resistance to tenofovir, didanosine and abacavir; RT mutation
L74V confers resistance to didanosine and abacavir; the
K103N RT mutation engenders resistance to the NNRTIs
efavirenz and nevirapine; the Q151M RT mutation causes
resistance to AZT, D4T, didenosine and abacavir through the
decreased incorporation mechanism; Y181C causes resis-
tance to nevirapine, etravirine and rilpivirine; M184V/I
confers resistance to 3TC and FTC, and also affects
resistance to rilpivirine; and finally, T215Y causes resistance
to AZT and D4T through the excision mechanism. In
addition, mutations at the 30, 46, 48, 50, 54, 82, 84 and 90
sites of the HIV-1 PR coding region cause resistance to all
known protease inhibitors: specifically, D30N causes resis-
tance to nelfinavir; M46I/L causes resistance to nelfinavir and
indinavir; G48V/M causes resistance to atazanavir, nelfinavir
and saquinavir; I50L/V causes resistance to atazanavir,
darunavir, fosamprenavir and lopinavir; and mutations at
TABLE 3. Comparison of the results obtained by the RFMP and direct sequencing assays in 100 clinical specimens
pol gene Codon Discordant (n) Concordant (n)
Compatible (n) Amino acid
RFMP only Direct sequencing only RFMP Direct sequencing
RT 65 3 97 – –
69 3 97 – –
74 3 97 – –
103 3 97 – –
106 3 96 1 – V/A V
151 3 97 – –
181 3 97 – –
184 3 97 – –
215 3 94 3 – T/F T/F or I/S or T/I/F
T/Y T/Y or N/S or T/S/Y
T/Y T/Y or N/S or T/S/Y
PR 30 – 100 – –
46 – 100 – –
48 – 100 – –
50 – 100 – –
54 – 100 – –
82 – 99 1 – V/A V
84 – 99 1 – I/V V
90 – 100 – –
RT, reverse transcriptase; PR, protease.
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residues 54, 82, 84 and 90 cause resistance to all protease
inhibitors to a varying extent (http://hivdb.stanford.edu/DR/
PIResiNote.html).
The detection limit of the RFMP assay was determined to be
223.02 copies/mL and able to identify a minority mutant at a
concentration as low as 5% of the circulating mixed popula-
tions, whereas the detection limit of the direct sequencing
method was 1268.11 copies/mL and able to detect variants
only when present at >20% of the total population (Table 2
and Fig. 1). A clear correlation was observed between
peak ratios and relative genotype concentration of mixed
populations.
The performance of the RFMP assay in detecting mutations
related to ARV drug-resistance was compared with direct
sequencing assays for 100 clinical samples from 60 HIV-1-
infected patients who experienced HAART therapy. The RFMP
assay successfully identified genotypic changes at all 17 codons
tested in clinical samples. Compared with direct sequencing,
the RFMP assay exhibited 96.6% concordance in the RT region
and 99.8% concordance in the PR region (Table 3 and Fig 2).
The PR data were not significantly more concordant than the
RT data (the difference was only two cases). The reason for
the slight difference is not clear, thus further investigation is
required with more samples. Notably, the RFMP assay
(a)
(b)
(c)
FIG. 2. Comparison of the RFMP and direct sequencing assays for detection of mixed genotypes. Sera were taken from patients infected with HIV-1
carrying ARV drug-resistant mutations and examined by the RFMP and sequencing assays. (a) For codon 103, molecular masses of 3088.0/3157.0 and
3113.0/3133.0 represent Lys (AAA) and Asn (AAC), respectively. (b) For codon 46, molecular masses of 2988.0/3164.0 and 3003.0/3148.0 represent
Met (ATG) and Ile (ATA), respectively. (c) For codon 215, molecular masses of 3740.4/3796.4 and 3724.4/3811.4 represent Thr (ACC) and Tyr
(TAC), respectively. Each codon was indicated by a red box in the sequencing chromatogram. AI is absolute intensity; m/z is mass-to-charge ratio.
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outperformed direct sequencing for the detection of single and
double mutations in compatible samples. The RFMP assay
detected 1% (1/100) more mutant viruses in codons 106, 82
and 84 and 3% (3/100) more mutant viruses in codon 215. All
discordances between the two assays were due to the inability
of the direct sequencing assay to identify the residues at nine
RT codons in three patients. Hence, the discrepancy among
the two assays may be due to a lower sensitivity of direct
sequencing.
HAART can clearly extend the life expectancy of HIV-1
patients. However, as adherence is usually imperfect, contin-
uous ARV drug-resistance testing can be an important man-
agement tool. There are two major methods of assessing ARV
drug-resistance: phenotypic assays and genotypic assays that
provide complementary information and be preferable to the
other [19,20]. Current treatment guidelines define as treatment
failure the detection of more than 200 copies/mL of HIV-1 RNA
[3]. However, existing genotypic assays, such as direct sequenc-
ing and the reverse hybridization-based assay, do not reliably
detect fewer than 1000 copies/ml of HIV-1 RNA, nor do they
enable detection of sequence variants present at <20% of
minority variants in mixed populations [21,22]. This perfor-
mance does not allow facile interpretation of ratios between
multiple virus mixtures, especially when a double mutation is
present in a single codon. While the reverse hybridization-
based assay has somewhat higher sensitivity than direct
sequencing it gives rise to false-positive and false-negative
results more frequently than direct sequencing [21–26].
With the advent of Next Generation Sequencing methods it
is possible to detect, by 454 pyrosequencing or an Illumina
Genome Analyzer, minor viral variants whose prevalence is
<1%. 454 pyrosequencing, also called ultra-deep pyrosequenc-
ing (UDPS), relies on fixing nebulized and adapter-ligated DNA
fragments to small DNA-capture beads in a water-in-oil
emulsion. The DNA fixed to these beads is then amplified by
PCR. An advantage of UDPS in the case of viral genomic analysis
is that it yields long sequence information for each sample
(average ~800 bases). However, UDPS has some technical
challenges. A major limitation of the UDPS relates to resolution
of homopolymer-containing DNA segments, such as AAA and
GGG [27]. Because there is no terminating moiety preventing
multiple consecutive incorporations at a given cycle, pyrose-
quencing relies on the magnitude of light emitted to determine
the number of repetitive bases. This is prone to greater error
than misincorporation. Hence, the dominant error type for the
454 platform is insertion-deletion, rather than substitution. The
decrease in single read accuracy from 99.4% for test fragments
to 96% for genomic libraries is primarily due to a lack of clonality
in a fraction of the genomic templates in the emulsion [28].
Moreover, based on current list prices for the UDPS, the
current cost for all the reagents, including the picotiter plate,
library preparation kits and emulsion PCR kits, to perform a
single experiment is $1000–7000 [29].
By combining the merits of unique assay chemistry and the
mature nature of MALDI-TOF mass spectrometry, the RFMP
assay can be used to screen for HIV drug-resistance mutations
in a robust high-throughput manner (e.g. 96 samples can be
analysed in 3 h with Bruker software (flexcontrol 3.0), which is
faster than existing hybridization or sequencing-based meth-
ods). In terms of cost-effectiveness, the direct cost per test
(reagents and labour) of the RFMP assay can be <$30, including
viral DNA extraction, PCR, restriction digestion, desalting and
matrix for mass analysis, which is cheaper than the sequencing
or hybridization assays that are c. $50–100 per test. These costs
do not include the equipment costs, which are slightly greater
for the RFMP method. However, with the advent of many
diagnostic assays operating on a mass spectrometer platform,
such as clinical genotyping and microorganism identification,
and the gradual spread of compact mass spectrometers into
laboratories as medical devices (i.e. Bruker Microflex), the
burden of the amortization cost should be substantially reduced
[30]. A limitation of the RFMP assay is that it determines only
molecular mass and is thus applicable only to known resistance
mutations andmay fail to detect DNA sequence changes that do
not affect molecular mass. Moreover, the occurrence of a novel
resistance mutation with sequence alterations that cause a
deviation from the predicted molecular mass pattern should be
addressed by periodic updating of mass patterns for unambig-
uous result interpretation from up-to-date HIV databases.
We demonstrate here that the mass spectrometry-based
RFMP assay is highly sensitive and able to successfully detect
HIV-1 carrying drug-resistant mutations that are present in <5%
of the total virus population. Hence, this assay can be used for
the efficient assessment of genotype dynamics of viral quasi-
species. Therefore, this simple procedure can be easily adapted
to a high-throughput format, should enable earlier detection of
drug-resistant viruses and help elucidate mechanisms of HIV-1
resistance, as well as guide and optimize treatment decisions.
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